Compare Bank of Nova Scotia (BNS) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Crispr Therapeutics AG — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $108.32B), while Crispr Therapeutics AG trades at $53.9 (market cap $5.23B). The key difference: Bank of Nova Scotia is far larger — about 20.7× Crispr Therapeutics AG's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BNS | CRSP | |
|---|---|---|
Market Cap | $108.32B | $5.23B |
Sector | Financials | Health |
52-Week High | $90.29 | $76.78 |
52-Week Low | $56.41 | $44.34 |
Dividend Yield | 3.64% | — |
Enterprise Value | — | $3.65B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
